Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib-Rituximab in Newly Diagnosed MCL
NCT05504603Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05504603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504603.